Abstract 1815
Background
Leukocytosis is common in patients with malignancies and might be a negative prognostic factor in lung cancer (LC). Leukocytes are, however, a heterogenous population of blood cells. Therefore, subpopulation of leukocytes responsible for this effect should be identified. It is presumed that neutrophilia and lymphocytopenia might be a negative factor in patients with lung cancer.
Methods
Leukocyte, absolute neutrophil, lymphocyte, eosinophil, basophil and thrombocyte count were determined before beginning of treatment in patients with LC. Patients with recent bleeding, elevated CRP or treated with best-supportive care were excluded. The impact of leukocytosis, neutrophilia, lymphocytopenia, eosinophilia and basophilia on progression- free survival (PFS) was determined. Neutrophils to lymphocytes ratio (NLR) at various cut-offs were determined along with platelets to lymphocytes ratio (PLR) and their effect on PFS was assessed. Kaplan- Meier and Cox- regression statistical analysis were used.
Results
200 patients were examined in our retrospective study. Median PFS was 7.41 months. Leukocytosis and neutrophilia significantly worsened PFS in patients with LC [HR 0.5200, (95%CI 0.3684 to 0.7340), P < 0.0001 and HR 0.5556 (95%CI 0.4068 to 0.7589) P = 0.0001]. These results were confirmed in Cox- regression analysis (covariates: age, gender, stage). Lymphocytopenia, basophilia, eosinophilia and thrombocytosis had no impact on survival rates. Elevated NLR (cut- off 3.54) significantly worsened PFS in patients with LC [HR 0.6069 (95%CI 0.4475 to 0.8231), P = 0.0013] even after adjustment to covariates (age, gender, stage). Elevated NLR at lower cut-offs (2.15 and 1.77) and elevated PLR (cut-off 123) did not affect the survival rate.
Conclusions
Neutrophilia appears to be a negative prognostic factor in patients with LC. Impairment in other white blood cell lines does not affect PFS, however, significantly elevated NLR (≥ 3.54) seems to have detrimental effect on survival rates.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty Hospital Trencin, Department of Oncology.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5052 - Identification of first-in-class, naturally occurring LAG3 checkpoint inhibitor
Presenter: Gennady Bratslavsky
Session: Poster Display session 1
Resources:
Abstract
5336 - Are Epigenetic therapies modifying sensitivity to conventional chemotherapy?
Presenter: Alexandra Bizot
Session: Poster Display session 1
Resources:
Abstract
5739 - Oncogenic mutations at the dimer interface of EGFR lead to formation of covalent homo-dimers and allosteric activation of the kinase domain: A mechanism which alters the selectivity profile of oncogenic EGFR.
Presenter: Elizabeth Buck
Session: Poster Display session 1
Resources:
Abstract
5492 - Basic selective estrogen receptor degraders (B-SERDs) in combination with novel BET inhibitors in ER+ breast cancer
Presenter: Rui Xiong
Session: Poster Display session 1
Resources:
Abstract
5965 - EPI-7386 is a novel N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer
Presenter: Ronan Le Moigne
Session: Poster Display session 1
Resources:
Abstract
3582 - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumors, and sensitizes tumors to immune checkpoint inhibitors.
Presenter: Tina Gruosso
Session: Poster Display session 1
Resources:
Abstract
1996 - High NAMPT expression and anti-tumor activity of NAMPT inhibitor in adult T-cell leukemia/lymphoma
Presenter: Tomohiro Kozako
Session: Poster Display session 1
Resources:
Abstract
4307 - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers
Presenter: Alexander Drilon
Session: Poster Display session 1
Resources:
Abstract
4869 - In Vivo Evaluation of Cisplatin-loaded PEG-PCL Block Copolymeric Nanoparticles for Anticancer Drug Delivery
Presenter: Yingtzu Yen
Session: Poster Display session 1
Resources:
Abstract
5054 - Inhibition of Rspo-Wnt pathway Facilitates Checkpoint Blockade Therapy by anti-RSPO3 antibody (DBPR117)
Presenter: John Hsu
Session: Poster Display session 1
Resources:
Abstract